ITPD20020271A1 - Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. - Google Patents

Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Info

Publication number: ITPD20020271A1
Authority: IT; Italy
Prior art keywords: hyaluronic acid; derivatives; chemical; covalently linked; pharmaceutical compounds
Prior art date: 2002-10-18

Application number

IT000271A

Other languages

English (en)

Inventor

Luca Gilda De

Bettolo Rinaldo Marini

Luisa Maria Migneco

Original Assignee

Fidia Farmaceutici

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-18

Filing date

2002-10-18

Publication date

2004-04-19

2002-10-18 Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici

2002-10-18 Priority to IT000271A priority Critical patent/ITPD20020271A1/it

2003-10-10 Priority to CN200380101570XA priority patent/CN1705683B/zh

2003-10-10 Priority to JP2004544138A priority patent/JP4704753B2/ja

2003-10-10 Priority to CA2783175A priority patent/CA2783175C/en

2003-10-10 Priority to PCT/EP2003/011239 priority patent/WO2004035629A2/en

2003-10-10 Priority to PL03376349A priority patent/PL376349A1/xx

2003-10-10 Priority to ES03748126T priority patent/ES2320439T3/es

2003-10-10 Priority to US10/531,853 priority patent/US7897584B2/en

2003-10-10 Priority to AU2003267441A priority patent/AU2003267441B2/en

2003-10-10 Priority to BR0315431-9A priority patent/BR0315431A/pt

2003-10-10 Priority to DE60325760T priority patent/DE60325760D1/de

2003-10-10 Priority to ES08169661.9T priority patent/ES2544481T3/es

2003-10-10 Priority to SI200331554T priority patent/SI1560854T1/sl

2003-10-10 Priority to RU2005115116/04A priority patent/RU2384593C2/ru

2003-10-10 Priority to NZ547668A priority patent/NZ547668A/en

2003-10-10 Priority to EP03748126A priority patent/EP1560854B1/en

2003-10-10 Priority to NZ540034A priority patent/NZ540034A/en

2003-10-10 Priority to DK03748126T priority patent/DK1560854T3/da

2003-10-10 Priority to HRP20050416AA priority patent/HRP20050416B1/hr

2003-10-10 Priority to CA2502531A priority patent/CA2502531C/en

2003-10-10 Priority to HK06101058.1A priority patent/HK1082753B/en

2003-10-10 Priority to PT03748126T priority patent/PT1560854E/pt

2003-10-10 Priority to KR1020057006412A priority patent/KR101076414B1/ko

2003-10-10 Priority to PL392566A priority patent/PL216861B1/pl

2003-10-10 Priority to AT03748126T priority patent/ATE420117T1/de

2003-10-10 Priority to EP20080169661 priority patent/EP2045270B1/en

2004-04-19 Publication of ITPD20020271A1 publication Critical patent/ITPD20020271A1/it

2005-04-17 Priority to IL168086A priority patent/IL168086A/en

2005-05-18 Priority to NO20052399A priority patent/NO333042B1/no

2011-01-21 Priority to US13/011,172 priority patent/US8034795B2/en

Links

KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 8
229920002674 hyaluronan Polymers 0.000 title abstract 5
229960003160 hyaluronic acid Drugs 0.000 title abstract 5
150000001875 compounds Chemical class 0.000 title 1
229940123237 Taxane Drugs 0.000 abstract 4
230000015572 biosynthetic process Effects 0.000 abstract 2
238000003786 synthesis reaction Methods 0.000 abstract 2
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
229960003668 docetaxel Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
125000006850 spacer group Chemical group 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Polymers & Plastics (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Epoxy Compounds (AREA)

IT000271A 2002-10-18 2002-10-18 Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. ITPD20020271A1 (it)

Priority Applications (29)

Application Number	Priority Date	Filing Date	Title
IT000271A ITPD20020271A1 (it)	2002-10-18	2002-10-18	Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
RU2005115116/04A RU2384593C2 (ru)	2002-10-18	2003-10-10	Таксаны, ковалентно связанные с гиалуроновой кислотой или производными гиалуроновой кислоты
EP03748126A EP1560854B1 (en)	2002-10-18	2003-10-10	Taxanes covalently bound to hyaluronic acid or hyaluronic acid derivatives
CA2783175A CA2783175C (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
PCT/EP2003/011239 WO2004035629A2 (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
PL03376349A PL376349A1 (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
ES03748126T ES2320439T3 (es)	2002-10-18	2003-10-10	Taxanos unidos covalentemente al acido hialuronico o a derivados del acido hialuronico.
US10/531,853 US7897584B2 (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
AU2003267441A AU2003267441B2 (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
BR0315431-9A BR0315431A (pt)	2002-10-18	2003-10-10	Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico
DE60325760T DE60325760D1 (de)	2002-10-18	2003-10-10	Kovalent an hyaluronsäure oder dessen derivate gebundene taxane
ES08169661.9T ES2544481T3 (es)	2002-10-18	2003-10-10	Taxanos unidos covalentemente a ácido hialurónico
SI200331554T SI1560854T1 (sl)	2002-10-18	2003-10-10	Taksani, kovalentno vezani na hiarulonsko kislino ali derivate hiarulonske kisline
CN200380101570XA CN1705683B (zh)	2002-10-18	2003-10-10	与透明质酸或透明质酸衍生物共价键合的紫杉烷
NZ547668A NZ547668A (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
DK03748126T DK1560854T3 (da)	2002-10-18	2003-10-10	Taxaner kovalent bundet til hyaluronsyre eller hyaluronsyrederivater
HK06101058.1A HK1082753B (en)		2003-10-10	Taxanes covalently bound to hyaluronic acid or hyaluronic acid derivatives
NZ540034A NZ540034A (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
HRP20050416AA HRP20050416B1 (hr)	2002-10-18	2003-10-10	Taksani kovalentno vezani na hialuronsku kiselinu ili derivate hialuronske kiseline
CA2502531A CA2502531C (en)	2002-10-18	2003-10-10	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
JP2004544138A JP4704753B2 (ja)	2002-10-18	2003-10-10	ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類
PT03748126T PT1560854E (pt)	2002-10-18	2003-10-10	Taxanos ligados covalentemente ao ácido hialurónico ou a derivados do ácido hialurónico
KR1020057006412A KR101076414B1 (ko)	2002-10-18	2003-10-10	히알루론산 또는 히알루론산 유도체에 공유적으로 결합된탁산
PL392566A PL216861B1 (pl)	2002-10-18	2003-10-10	Taksany kowalencyjnie związane z kwasem hialuronowym lub pochodnymi kwasu hialuronowego, sposób ich otrzymywania, kompozycja je zawierająca oraz zastosowanie
AT03748126T ATE420117T1 (de)	2002-10-18	2003-10-10	Kovalent an hyaluronsäure oder dessen derivate gebundene taxane
EP20080169661 EP2045270B1 (en)	2002-10-18	2003-10-10	Taxanes covalently bound to hyaluronic acid
IL168086A IL168086A (en)	2002-10-18	2005-04-17	Taxanes covalently bonded to hyaluronic acid or hyaluronic acid derivatives
NO20052399A NO333042B1 (no)	2002-10-18	2005-05-18	Taksan, fremstilling og anvendelse, samt preparat omfattende taksan.
US13/011,172 US8034795B2 (en)	2002-10-18	2011-01-21	Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT000271A ITPD20020271A1 (it)	2002-10-18	2002-10-18	Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Publications (1)

Publication Number	Publication Date
ITPD20020271A1 true ITPD20020271A1 (it)	2004-04-19

Family

ID=32104794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IT000271A ITPD20020271A1 (it)	2002-10-18	2002-10-18	Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Country Status (22)

Country	Link
US (2)	US7897584B2 (it)
EP (2)	EP1560854B1 (it)
JP (1)	JP4704753B2 (it)
KR (1)	KR101076414B1 (it)
CN (1)	CN1705683B (it)
AT (1)	ATE420117T1 (it)
AU (1)	AU2003267441B2 (it)
BR (1)	BR0315431A (it)
CA (2)	CA2502531C (it)
DE (1)	DE60325760D1 (it)
DK (1)	DK1560854T3 (it)
ES (2)	ES2544481T3 (it)
HR (1)	HRP20050416B1 (it)
IL (1)	IL168086A (it)
IT (1)	ITPD20020271A1 (it)
NO (1)	NO333042B1 (it)
NZ (2)	NZ547668A (it)
PL (2)	PL376349A1 (it)
PT (1)	PT1560854E (it)
RU (1)	RU2384593C2 (it)
SI (1)	SI1560854T1 (it)
WO (1)	WO2004035629A2 (it)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7923431B2 (en)	2001-12-21	2011-04-12	Ferrosan Medical Devices A/S	Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
ES2331791T5 (es)	2002-06-26	2016-01-21	Medigene Ag	Método de producción de una preparación catiónica de liposomas que comprende un compuesto lipófilo
CN101001649B (zh)	2004-07-09	2011-08-31	弗罗桑医疗设备公司	包括透明质酸的止血组合物及其制备方法
EP1905456A4 (en)	2005-07-06	2010-12-22	Seikagaku Kogyo Co Ltd	PHARMACEUTICAL LIGHT-NETWORKED HYALURONIC DERIVATIVE GEL
ITPD20050242A1 (it)	2005-08-03	2007-02-04	Fidia Farmaceutici	Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
EP1973952A4 (en) *	2006-01-23	2010-09-01	Kwangju Inst Sci & Tech	CONJUGATE COMPRISING A COVALENT TO A MUCOADHESIVE POLYMER-ASSOCIATED PHARMACEUTICALLY ACTIVE COMPOUND, AND A TRANSMUCOSAL ADMINISTRATION METHOD FOR A PHARMACEUTICALLY ACTIVE COMPOUND USING THEREOF
IE20060049A1 (en) *	2006-01-25	2007-08-08	Eurand Pharmaceuticals Ltd	A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
CN101501075B (zh) *	2006-08-04	2013-07-10	诺维信生物制药丹麦公司	支化透明质酸和制造方法
WO2008089256A2 (en) *	2007-01-16	2008-07-24	Cappella, Inc.	Polymeric therapeutics
ITMI20071267A1 (it)	2007-06-22	2008-12-23	Fidia Farmaceutici	Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
ITMI20071341A1 (it)	2007-07-05	2009-01-06	Fidia Farmaceutici	Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
IE20070900A1 (en) *	2007-12-12	2009-06-24	Eurand Pharmaceuticals Ltd	New anticancer conjugates
WO2009097570A2 (en) *	2008-01-30	2009-08-06	University Of Kansas	Intralymphatic chemotherapy drug carriers
CN102014973A (zh)	2008-02-29	2011-04-13	弗罗桑医疗设备公司	用于促进止血和/或伤口愈合的装置
US9925209B2 (en)	2008-03-19	2018-03-27	The Board Of Regents Of The University Of Oklahoma	Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en)	2008-03-19	2017-06-27	The Board Of Regents Of The University Of Oklahoma	Heparosan polymers and methods of making and using same for the enhancement of therapeutics
IT1391006B1 (it) *	2008-10-08	2011-10-27	Fidia Farmaceutici	Uso terapeutico di nuove preparazioni farmaceutiche contenenti farmaci antitumorali legati all'acido ialuronico nel trattamento delle neoplasie
US9789200B2 (en)	2008-04-22	2017-10-17	Fidia Farmaceutici S.P.A.	Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
WO2010030342A2 (en) *	2008-09-09	2010-03-18	The Board Of Regents Of The University Of Oklahoma	Heparosan polymers and methods of making and using same for the enhancement of therapeutics
JP5542687B2 (ja)	2008-11-05	2014-07-09	国立大学法人東京医科歯科大学	ヒアルロン酸誘導体、およびその医薬組成物
IT1397247B1 (it) *	2009-05-14	2013-01-04	Fidia Farmaceutici	Nuovi agenti regolatori dell'attivita' citochinica
IT1399351B1 (it) *	2009-06-16	2013-04-16	Fidia Farmaceutici	Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR20110032561A (ko) *	2009-09-23	2011-03-30	포항공과대학교 산학협력단	약물 전달체의 표적 특이성 조절 방법, 표적 특이적 약물 전달체, 및 표적-비특이적 약효 장기 지속성 약물 전달체
US8722644B2 (en)	2010-01-04	2014-05-13	Holy Stone Healthcare Co., Ltd.	Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
WO2012086857A1 (ko) *	2010-12-21	2012-06-28	(주)파낙스이엠	광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
WO2013131520A2 (en)	2012-03-06	2013-09-12	Ferrosan Medical Devices A/S	Pressurized container containing haemostatic paste
CN104168927B (zh) *	2012-03-27	2016-10-05	泰尔茂株式会社	涂布组合物及医疗器械
RU2636240C2 (ru)	2012-06-12	2017-11-21	Ферросан Медикал Дивайсиз А/С	Сухая гемостатическая композиция
CN104603156B (zh)	2012-09-05	2016-10-26	中外制药株式会社	引入有氨基酸和甾基的透明质酸衍生物
US9635795B2 (en)	2012-10-23	2017-04-25	International Business Machines Corporation	Multiple expansion card insertion and extraction tool
CN103641925B (zh) *	2012-11-27	2016-08-17	王晖	水溶性多聚糖与紫杉烷类化合物的共价聚化合物，其制备方法及医药用途
EP3010419B1 (en)	2013-06-21	2020-05-20	Ferrosan Medical Devices A/S	Vacuum expanded dry composition and syringe for retaining same
US10675354B2 (en)	2013-07-10	2020-06-09	Seikagaku Corporation	Glycosaminoglycan derivative and method for producing same
US10098962B2 (en)	2013-07-10	2018-10-16	Seikagaku Corporation	Glycosaminoglycan derivative and method for producing same
JP6489485B2 (ja)	2013-12-11	2019-03-27	フェロサンメディカルデバイシーズエイ／エス	押し出し増強因子を含んでいる乾燥組成物
CN103861116A (zh) *	2014-03-06	2014-06-18	沈阳药大制剂新技术有限公司	一种抗肿瘤药物的前体药物及其制备和应用
EA032076B1 (ru) *	2014-07-31	2019-04-30	Себастьяно Шюто	Производные, полученные из гиалуроновой кислоты и карнозина
CN104198707B (zh) *	2014-09-12	2016-09-14	范飞舟	N-乙酰氨基葡萄糖在制备检测肿瘤的试剂盒中的应用
CA2960309A1 (en)	2014-10-13	2016-04-21	Ferrosan Medical Devices A/S	Dry composition for use in haemostasis and wound healing
CN104491875A (zh) *	2014-12-22	2015-04-08	中国药科大学	一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
RU2705905C2 (ru)	2014-12-24	2019-11-12	Ферросан Медикал Дивайсиз А/С	Шприц для удерживания и смешивания первого и второго веществ
US10350236B2 (en) *	2015-01-09	2019-07-16	Seikagaku Corporation	Chondroitin sulfate derivative and agent for treating bladder diseases
EP3302569A1 (en) *	2015-05-29	2018-04-11	Albatross Technologies Limited	Cross-linked hyaluronic acid for drug delivery and pharmaceutical preparation using same
AU2016290433B2 (en)	2015-07-03	2018-05-24	Ferrosan Medical Devices A/S	Syringe for mixing two components and for retaining a vacuum in a storage condition
CN108178803B (zh) *	2017-09-25	2020-03-10	温州医科大学	一种载药的肉桂醛-葡聚糖聚合物自组装纳米粒的制备及其抗肿瘤应用
WO2019098393A1 (ja)	2017-11-15	2019-05-23	中外製薬株式会社	ポリエチレングリコールにより修飾されたヒアルロン酸誘導体
CN108219029A (zh) *	2018-03-22	2018-06-29	盐城师范学院	一种水溶性卡巴他赛抗癌药物的制备方法
CN108467439A (zh) *	2018-03-22	2018-08-31	盐城师范学院	一种水溶性紫杉醇抗癌药物的制备方法
ES2968412T3 (es)	2018-05-09	2024-05-09	Ferrosan Medical Devices As	Método para preparar una composición hemostática
EP3812376A4 (en) *	2018-06-20	2022-08-17	Santolecan Pharmaceuticals LLC	TWO-COMPONENT CONJUGATE OF PACLITAXEL-LIPID-POLYSACCHARIDE, METHOD FOR ITS PREPARATION AND ITS USE
IT201800009731A1 (it) *	2018-10-25	2020-04-25	Fidia Farm Spa	Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
CN111588914A (zh) *	2019-12-31	2020-08-28	辽宁垠艺生物科技股份有限公司	介入或植入医疗器械的药物涂层及其制备方法
IT202000007747A1 (it)	2020-04-10	2021-10-10	Fidia Farm Spa	Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) *	2020-04-17	2021-10-17	Fidia Farm Spa	Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel
CN111892668B (zh) *	2020-07-03	2022-07-12	广东工业大学	一种化合物及其制备方法、荧光探针和抗肿瘤药物
CN117838875B (zh) *	2020-07-15	2025-01-24	上海椿安生物医药科技有限公司	用于局部递送治疗剂的药物递送系统以及其用途
CN114870031B (zh) *	2022-05-20	2023-07-07	四川大学	一种cd44靶向的紫杉烷类纳米晶体及其制备方法与应用
WO2024038087A1 (en) *	2022-08-16	2024-02-22	Synartro Ab	Method for preparing sterile compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4851521A (en) *	1985-07-08	1989-07-25	Fidia, S.P.A.	Esters of hyaluronic acid
GB8713662D0 (en) *	1987-06-11	1987-07-15	Skandigen Ab	Hyaluronic acid derivatives
IT1219587B (it)	1988-05-13	1990-05-18	Fidia Farmaceutici	Polisaccaridi carbossiilici autoreticolati
US5356883A (en)	1989-08-01	1994-10-18	Research Foundation Of State University Of N.Y.	Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
EP0506976B1 (en) *	1990-10-18	1997-04-09	Shiseido Company Limited	Combination of hyaluronic acid with medicinal ingredient and production thereof
JP2604930B2 (ja) *	1990-12-14	1997-04-30	株式会社ディ・ディ・エス研究所	ヒアルロン酸およびコンドロイチン誘導体
AU4406793A (en) *	1992-06-04	1993-12-30	Clover Consolidated, Limited	Water-soluble polymeric carriers for drug delivery
US5817321A (en) *	1992-10-08	1998-10-06	Supratek Pharma, Inc.	Biological agent compositions
JP2610792B2 (ja) *	1993-02-26	1997-05-14	株式会社ディ・ディ・エス研究所	多糖誘導体および薬物担体
US5616568A (en)	1993-11-30	1997-04-01	The Research Foundation Of State University Of New York	Functionalized derivatives of hyaluronic acid
ITPD940054A1 (it)	1994-03-23	1995-09-23	Fidia Advanced Biopolymers Srl	Polisaccaridi solfatati
PL189698B1 (pl) *	1996-03-12	2005-09-30	Pg Txl Co	Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
CA2175282A1 (en)	1996-04-29	1997-10-30	Rudolf Edgar Falk	Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2208924A1 (en)	1997-07-09	1999-01-09	Hyal Pharmaceutical Corporation	Sparing paclitaxel by the use of hyaluronan
WO1999059603A1 (en) *	1998-05-20	1999-11-25	Chugai Seiyaku Kabushiki Kaisha	Remedies for joint diseases bound to hyaluronic acid
ITPD980169A1 (it)	1998-07-06	2000-01-06	Fidia Advanced Biopolymers Srl	Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
ATE218560T1 (de)	1998-08-21	2002-06-15	Pharmachemie Bv	Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
EP1140198B1 (en)	1999-01-13	2007-10-31	Alchemia Oncology Pty Limited	Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
JP2001081103A (ja) *	1999-09-13	2001-03-27	Denki Kagaku Kogyo Kk	ヒアルロン酸結合薬剤
US6593308B2 (en)	1999-12-03	2003-07-15	The Regents Of The University Of California	Targeted drug delivery with a hyaluronan ligand
US7125858B2 (en)	1999-12-28	2006-10-24	Bioniche Life Sciences Inc.	Hyaluronic acid in the treatment of cancer
IT1317359B1 (it)	2000-08-31	2003-06-16	Fidia Advanced Biopolymers Srl	Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e
IT1317358B1 (it)	2000-08-31	2003-06-16	Fidia Advanced Biopolymers Srl	Derivati cross-linkati dell'acido ialuronico.

2002
- 2002-10-18 IT IT000271A patent/ITPD20020271A1/it unknown
2003
- 2003-10-10 AU AU2003267441A patent/AU2003267441B2/en not_active Expired
- 2003-10-10 EP EP03748126A patent/EP1560854B1/en not_active Expired - Lifetime
- 2003-10-10 HR HRP20050416AA patent/HRP20050416B1/hr not_active IP Right Cessation
- 2003-10-10 WO PCT/EP2003/011239 patent/WO2004035629A2/en not_active Ceased
- 2003-10-10 DE DE60325760T patent/DE60325760D1/de not_active Expired - Lifetime
- 2003-10-10 JP JP2004544138A patent/JP4704753B2/ja not_active Expired - Lifetime
- 2003-10-10 CA CA2502531A patent/CA2502531C/en not_active Expired - Lifetime
- 2003-10-10 CA CA2783175A patent/CA2783175C/en not_active Expired - Lifetime
- 2003-10-10 CN CN200380101570XA patent/CN1705683B/zh not_active Expired - Lifetime
- 2003-10-10 PL PL03376349A patent/PL376349A1/xx unknown
- 2003-10-10 RU RU2005115116/04A patent/RU2384593C2/ru active
- 2003-10-10 NZ NZ547668A patent/NZ547668A/en not_active IP Right Cessation
- 2003-10-10 US US10/531,853 patent/US7897584B2/en not_active Expired - Lifetime
- 2003-10-10 AT AT03748126T patent/ATE420117T1/de active
- 2003-10-10 PL PL392566A patent/PL216861B1/pl unknown
- 2003-10-10 ES ES08169661.9T patent/ES2544481T3/es not_active Expired - Lifetime
- 2003-10-10 ES ES03748126T patent/ES2320439T3/es not_active Expired - Lifetime
- 2003-10-10 PT PT03748126T patent/PT1560854E/pt unknown
- 2003-10-10 BR BR0315431-9A patent/BR0315431A/pt not_active IP Right Cessation
- 2003-10-10 DK DK03748126T patent/DK1560854T3/da active
- 2003-10-10 KR KR1020057006412A patent/KR101076414B1/ko not_active Expired - Lifetime
- 2003-10-10 EP EP20080169661 patent/EP2045270B1/en not_active Expired - Lifetime
- 2003-10-10 SI SI200331554T patent/SI1560854T1/sl unknown
- 2003-10-10 NZ NZ540034A patent/NZ540034A/en not_active IP Right Cessation
2005
- 2005-04-17 IL IL168086A patent/IL168086A/en unknown
- 2005-05-18 NO NO20052399A patent/NO333042B1/no not_active IP Right Cessation
2011
- 2011-01-21 US US13/011,172 patent/US8034795B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO20052399D0 (no)	2005-05-18
EP2045270A3 (en)	2009-06-03
NZ547668A (en)	2008-04-30
JP2006504747A (ja)	2006-02-09
EP1560854A2 (en)	2005-08-10
IL168086A (en)	2010-11-30
CN1705683B (zh)	2010-04-28
US7897584B2 (en)	2011-03-01
DE60325760D1 (de)	2009-02-26
WO2004035629A3 (en)	2004-06-24
ATE420117T1 (de)	2009-01-15
US20110159052A1 (en)	2011-06-30
PL392566A1 (pl)	2010-11-22
EP2045270B1 (en)	2015-05-06
WO2004035629A2 (en)	2004-04-29
CA2502531A1 (en)	2004-04-29
RU2005115116A (ru)	2006-01-20
AU2003267441A1 (en)	2004-05-04
JP4704753B2 (ja)	2011-06-22
PL376349A1 (en)	2005-12-27
KR101076414B1 (ko)	2011-10-25
NZ540034A (en)	2007-11-30
EP1560854B1 (en)	2009-01-07
ES2544481T3 (es)	2015-08-31
CN1705683A (zh)	2005-12-07
SI1560854T1 (sl)	2009-06-30
US20060116346A1 (en)	2006-06-01
BR0315431A (pt)	2005-08-16
PL216861B1 (pl)	2014-05-30
HRP20050416B1 (hr)	2013-09-30
CA2783175A1 (en)	2004-04-29
DK1560854T3 (da)	2009-04-20
CA2783175C (en)	2013-12-24
AU2003267441B2 (en)	2010-01-14
PT1560854E (pt)	2009-04-15
ES2320439T3 (es)	2009-05-22
WO2004035629A8 (en)	2005-06-09
NO333042B1 (no)	2013-02-18
CA2502531C (en)	2012-10-02
RU2384593C2 (ru)	2010-03-20
US8034795B2 (en)	2011-10-11
HRP20050416A2 (en)	2006-02-28
EP2045270A2 (en)	2009-04-08
NO20052399L (no)	2005-05-18
KR20050065595A (ko)	2005-06-29
WO2004035629A9 (en)	2005-07-07
HK1082753A1 (en)	2006-06-16

Publication	Publication Date	Title
BR0315431A (pt)	2005-08-16	Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico
TWI366464B (en)	2012-06-21	Cyclodextrin-based polymers for therapeutics delivery
ATE342054T1 (de)	2006-11-15	Verfahren und zusammansetzung zur behandlung von krebs
GB0313612D0 (en)	2003-07-16	Organic compounds
DE60003863D1 (de)	2003-08-21	Dioxocyclopentylhydroxamsäure
TW200519106A (en)	2005-06-16	Organic compounds
MY142029A (en)	2010-08-16	Phenoxyacetic acid derivatives
CY1110115T1 (el)	2015-01-14	Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες
ATE517621T1 (de)	2011-08-15	Verwendung von ampk-aktivierenden imidazol- derivaten, herstellungsverfahren dafür und diese enthaltende pharmazeutische zusammensetzungen
EA200801132A1 (ru)	2009-02-27	Новые улучшенные композиции для лечения рака
DE602005017895D1 (de)	2010-01-07	Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
CY1110896T1 (el)	2013-09-04	Μια νεα αντιμυκητιακη συνθεση
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
BRPI0508177A (pt)	2007-08-07	composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
PL1797088T3 (pl)	2011-06-30	Nowe pochodne chromen-2-onu i ich zastosowanie jako inhibitorów wychwytu zwrotnego neurotransmiteru monoaminowego
WO2008078453A1 (ja)	2008-07-03	血小板産生促進因子及びその利用
ATE430126T1 (de)	2009-05-15	Neue dibenzoäb,füoxepin-10-carbonsäureamide und deren pharmazeutische anwendungen
LV15575A (lv)	2021-06-20	Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
BRPI0207141B8 (pt)	2021-05-25	processo para preparar compostos, uso de compostos, composição farmacêutica e método para tratamento de câncer
ATE440826T1 (de)	2009-09-15	Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
CY1107483T1 (el)	2013-03-13	Παραγωγα πυριδαζινης, η χρηση τους ως φαρμακευτικα σκευασματα και η διαδικασια παρασκευης τους
ATE537162T1 (de)	2011-12-15	Vitamin-d-derivate, die auf den nuklearen vitamin-d-rezeptor wirken, deren herstellung und deren anwendungen
EP1931735A4 (en)	2010-07-14	HIGH-purity TEXAPHYRINMETAL COMPLEXES
UA93197C2 (ru)	2011-01-25	Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)
BR0313228A (pt)	2005-06-14	Derivados de poliisoprenila - benzofenona, processo para sua preparação, e emprego dos mesmos